Health · Pharma & Biotech · 5 hrs ago
Dongwha Pharmaceutical launches combination treatment for mixed dyslipidemia
Dongwha Pharmaceutical launched Pravafen Capsules in South Korea on October 22 for a form of abnormal blood-fat levels called mixed dyslipidemia.
The medicine is intended for high-risk adults whose LDL is controlled but triglycerides remain high and HDL low despite treatment with pravastatin alone.
LDL is often called “bad” cholesterol, while HDL is often called “good” cholesterol; triglycerides are another type of fat in the blood.
One capsule combines pravastatin and fenofibric acid: pravastatin lowers LDL, while fenofibric acid helps lower triglycerides and improve HDL.
It is approved to be taken once each evening, with or without food, and the company says the capsule is smaller than existing combination products.
Dongwha plans to hold a launch symposium in Seoul on October 31 to discuss treatment strategies and the medicine’s clinical use.
Dongwha Pharmaceutical has launched Pravafen capsules, a combination treatment for mixed dyslipidemia.
The capsule combines pravastatin sodium 40 mg with fenofibric acid 110 mg.
It is intended for high-risk adults whose LDL cholesterol is controlled with pravastatin alone but who still have high triglycerides and low HDL cholesterol.
The medicine is approved for once-daily evening use, with or without food.
The company plans to hold a launch symposium in Seoul on October 31.
- Who
- Dongwha Pharmaceutical launched the treatment.
- What
- Pravafen capsules combine pravastatin sodium and fenofibric acid to treat mixed dyslipidemia.
- When
- The company announced the launch on October 22, 2026.
- Where
- The treatment was launched in South Korea. A launch symposium is planned in Seoul.
- Why
- It is intended for high-risk adults whose LDL cholesterol is controlled with pravastatin alone but who have high triglycerides and low HDL cholesterol.
This story does not have two clearly opposing sides.
Dongwha Pharmaceutical announced the launch of Pravafen capsules.
The company plans to hold a launch symposium at the Sofitel Ambassador Seoul Hotel in Jamsil, Seoul.
- Active ingredients
- Pravastatin sodium 40 mg and fenofibric acid 110 mg
- Dosing
- One capsule once daily in the evening, with or without food
- Intended patients
- High-risk adults with controlled LDL cholesterol but high triglycerides and low HDL cholesterol
- Launch date
- October 22, 2026
- Symposium
- October 31 at Sofitel Ambassador Seoul Hotel in Jamsil, Seoul
3 sources
What people are saying
Pravafen capsules were introduced to broaden treatment options for patients with mixed dyslipidemia
We plan to continue expanding our dyslipidemia treatment portfolio, taking into account the treatment environments of diverse patients